Wall M, Costanzo A, Le Tallec D, Isbrucker R
Health Canada, Biologic and Radiopharmaceuticals Drugs Directorate, Centre for Biologics Evaluation, 100 Eglantine Dr. A/L 0602B, Ottawa, Ontario, Canada, K1A 0K9.
European Directorate for the Quality of Medicines & HealthCare, Department of Biological Standardisation, OMCL Network & HealthCare (DBO), Council of Europe, Strasbourg, France.
Pharmeur Bio Sci Notes. 2021;2021:69-87.
Recently, the Chinese hamster ovary (CHO) cell-based clustering assay replaced the in vivo Histamine Sensitisation Test (HIST) in mice in European Pharmacopoeia (Ph. Eur.) general chapter 2.6.33. ‘Residual pertussis toxin’ as the recommended method to test for residual pertussis toxin in acellular pertussis vaccine intermediates. To support the standardised CHO clustering assay, availability of a reference standard is critical. Ph. Eur. pertussis toxin Biological Reference Preparation (BRP) batch 1 was first calibrated in International Units in 2008 for the HIST and subsequently also calibrated for the CHO clustering assay in 2017. However, its stocks were dwindling and needed to be replaced. In an effort to maintain adequate supply, a project (BSP141) was initiated by the European Directorate for the Quality of Medicines & HealthCare (EDQM), under the aegis of the Biological Standardisation Programme, to establish a second pertussis toxin BRP (BRP2). Candidate material was manufactured ad hoc by an acellular pertussis vaccine manufacturer and an optimal formulation for long-term stability was defined. Exhaustive in-process and post-production controls demonstrated that the material was fit for its intended purpose and therefore a collaborative study for calibration and stability assessment of the candidate material was organised, which included 10 laboratories worldwide. As a result of the study, the candidate material was established as Ph. Eur. Pertussis toxin BRP batch 2 with a potency of 130 IU/vial for the CHO clustering assay. Unopened vials must be stored at −20°C. The BRP may be used for up to two weeks after reconstitution if appropriately handled and stored at 2–8°C.
最近,基于中国仓鼠卵巢(CHO)细胞的聚类分析法取代了欧洲药典(Ph. Eur.)通则2.6.33“残留百日咳毒素”中用于检测无细胞百日咳疫苗中间体中残留百日咳毒素的小鼠体内组胺致敏试验(HIST),成为推荐方法。为支持标准化的CHO聚类分析法,参考标准品的可用性至关重要。欧洲药典百日咳毒素生物参考制剂(BRP)第1批于2008年首次以国际单位进行校准用于HIST,随后在2017年也校准用于CHO聚类分析法。然而,其库存日益减少,需要更换。为努力维持充足供应,欧洲药品质量管理局(EDQM)在生物标准化计划的支持下启动了一个项目(BSP141),以建立第二种百日咳毒素BRP(BRP2)。候选材料由一家无细胞百日咳疫苗制造商临时生产,并确定了用于长期稳定性的最佳配方。详尽的生产过程中和生产后控制表明该材料符合其预期用途,因此组织了一项针对候选材料校准和稳定性评估的协作研究,该研究包括全球10个实验室。研究结果是,候选材料被确立为欧洲药典百日咳毒素BRP第2批,用于CHO聚类分析法时效价为130 IU/瓶。未开封的小瓶必须储存在−20°C。如果妥善处理并储存在2–8°C,BRP复溶后最多可使用两周。